参麦注射液治疗慢性肺源性心脏病的疗效观察及机理的探讨

目的　观测参麦注射液对慢性肺源性心脏病的临床疗效并探讨其机理。方法　选择 72例慢性肺源性心脏病患者 ,随机分成两组 ,试验前均评价心功能及监测动脉血气、右室压 (RVP)、平均肺动脉压 (mPAP)、全血高切粘度、全血低切粘度、血浆粘度、红细胞压积、纤维蛋白原、血红蛋白定量和红细胞计数等指标。治疗组在常规治疗的同时合并给予参麦注射液 5 0ml/d ,稀释后ivgtt,疗程 2周 :对照组只给予常规治疗。 2周后 ,复测上述指标 ,比较各组前后的变化。结果　 (1)参麦组心力衰竭纠正有效率和动脉血气改善的有效率显著高于对照组 (P <0 .0 5 )。 (2 )参麦组试验前后比较 ,右室压 (PVP)、平均肺动脉压 (mPAP)均明显下降 (P <0 .0 5 ) ;而对照组无显著性变化 (P >0 .0 5 )。 (3)参麦组试验前后比较 ,全血高切粘度、全血低切、血浆粘度、红细胞压积、纤维蛋白原、血红蛋白定量和红细胞计数等指标均明显下降 (P <0 .0 5 ) ;而对照组则无显著变化 (P >0 .0 5 )。结论　参麦注射液对慢性肺源性心脏病具有纠正心力衰竭、降低肺动脉及右心室压力、改善血液流变和动脉血气的作用

Clinical Effects and Principle of Shenmai Injection in the Treatment of Chronic Cor Pulmonale

Objective To investigate the clinical effects of Shenmai Injection in treatment of chronic cor pulmonale and explore the principle of it.Methods Seventy-two chronic cor pulmonale patients were randomly assingned into two groups,all the patients were assaied the cardiac function and the levels of arteria blood gases,right ventricle pressure,average pulmonary artery pressure,blood viscosity,plasma viscosity,hematocrit(PCV),fibrinogen quantity,ferrohemoglobin quantity and RBC before the trial.In addition to the routine treatment,the patints of Shenmai group were given Shenmai In jection,intravenous drip(50 ml/d)for 2 weeks,while the patients of control group were only given routine treatment. Results (1)heart failure redressing rate and arteria blood gases ameliorating rate of Shenmai group were higher than control group(P<0.05).(2)weeks later,the markers of right ventricle pressure,average pulmonary artery pressure,blood viscosity,plasma viscosity,hematocrit, fibrinogen quantity,ferrohemoglobin quantity,RBC in Shenmai group were decreased(P<0.05),but there were no change in control group(P>05).Conclusion Shenmai Injection can redress heart failure,decrease the pressure of right ventricle and pulmonary artery and amelin orate arteria blood gases and hemorheology.